C12N 2310/334
Modified c
Official title: Modified C
C12N2310/334 (Modified c) appears on 1,156 US grants and 2,235 published applications in this corpus.
Search patents in C12N- Granted patents
- 1,156
- Published applications
- 2,235
- Assignees
- 395
- Inventors
- 1,946
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 2 | 0 |
| 1996 | 2 | 0 |
| 1997 | 12 | 0 |
| 1998 | 15 | 0 |
| 1999 | 37 | 0 |
| 2000 | 70 | 0 |
| 2001 | 54 | 7 |
| 2002 | 63 | 30 |
| 2003 | 30 | 183 |
| 2004 | 20 | 229 |
| 2005 | 15 | 87 |
| 2006 | 15 | 45 |
| 2007 | 12 | 40 |
| 2008 | 17 | 28 |
| 2009 | 23 | 45 |
| 2010 | 34 | 45 |
| 2011 | 26 | 55 |
| 2012 | 37 | 60 |
| 2013 | 40 | 56 |
| 2014 | 51 | 66 |
| 2015 | 51 | 93 |
| 2016 | 49 | 88 |
| 2017 | 52 | 81 |
| 2018 | 42 | 100 |
| 2019 | 58 | 95 |
| 2020 | 54 | 104 |
| 2021 | 66 | 107 |
| 2022 | 50 | 112 |
| 2023 | 40 | 121 |
| 2024 | 44 | 129 |
| 2025 | 46 | 130 |
| 2026 | 29 | 99 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Compounds and methods for reducing PLN expression22 Sep 2026US 12,742,170 B2Ionis Pharmaceuticals, Inc.
- Compounds and methods for reducing FUS expression15 Sep 2026US 12,735,700 B2Ionis Pharmaceuticals, Inc.
- Oligonucleotide compositions and methods of use thereof15 Sep 2026US 12,735,703 B2Wave Life Sciences Ltd.
- Modulation of GYS1 expression25 Aug 2026US 12,716,067 B2Ionis Pharmaceuticals, Inc.
- Therapeutics for glycogen storage disease type iii11 Aug 2026US 12,703,858 B2Ultragenyx Pharmaceutical Inc.
- Methods of treatment of chronic kidney disease8 Oct 2026US 2026/0308590 A1AstraZeneca AB
- Antisense oligomer formulations8 Oct 2026US 2026/0308595 A1Stoke Therapeutics, Inc.
- Trem compositions and methods of use1 Oct 2026US 2026/0297575 A1Flagship Pioneering Innovations VI, LLC
- Oligonucleotides comprising segmented gap structures1 Oct 2026US 2026/0297584 A1Ausperbio Therapeutics Inc.
- Modulation of Dystrophia Myotonica-Protein Kinase (DMPK) Expression1 Oct 2026US 2026/0297587 A1Ionis Pharmaceuticals, Inc.
Most cited
By later US patents
- Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides619US 5,596,091 AThe Regents of the University of California · 1997
- 2'deoxy-2'-alkylnucleotide containing nucleic acid521US 5,627,053 ARibozyme Pharmaceuticals, Inc. · 1997
- Oligoribonucleotides and ribonucleases for cleaving RNA486US 6,107,094 AIsis Pharmaceuticals, Inc. · 2000
- Oligoribonucleotides for cleaving RNA385US 5,898,031 AIsis Pharmaceuticals, Inc. · 1999
- RNA containing modified nucleosides and methods of use thereof353US 8,278,036 B2The Trustees of the University of Pennsylvania · 2012